# Clene (NASDAQ: CLNN) Discusses Developments of CNM-Au8(R), Novel Tech During Xtalks Podcast

* Clene’s mission is to transform the treatment of neurodegenerative diseases with a new class of drugs, potentially impacting the lives of millions
* The company’s uniquely structured gold nanocrystals have the remarkable ability to convert critical energetic metabolites in living cells for the production of ATP, the essential energy currency for cellular functions, offering disease combatting capabilities
* Clene is currently preparing for Phase 3 clinical trials of CNM-Au8for ALS and MS, following successful early studies

 Xtalks Life Science Podcast recently featured Karen S. Ho, PhD, Vice President of Translational Medicine for Clene (NASDAQ: CLNN), a late-stage biopharmaceutical company focused on protecting mitochondrial health and neuronal function to treat neurodegenerative diseases. In the episode, host Ayesha Rashid, PhD, discussed Clene’s innovative gold nanocrystal technology and how Dr. Ho is leading the company’s development in diseases like ALS (Amyotrophic Lateral Sclerosis), MS (Multiple Sclerosis), and PD (Parkinson’s Disease).

 Clene’s mission is to transform the treatment of neurodegenerative diseases with a unique approach, potentially impacting the lives of millions. They are pioneering a new class of drugs that integrates principles from chemistry, physics, and material science, and applying these to…

 Read More>>

 NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

 Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

 The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

 Corporate Communications

 IBN (InvestorBrandNetwork)Los Angeles, Californiawww.InvestorBrandNetwork.com310.299.1717 OfficeEditor@InvestorBrandNetwork.com 

[Original/Source Press Release](https://rss.investorbrandnetwork.com/ult-prem/clene-nasdaq-clnn-discusses-developments-of-cnm-au8r-novel-tech-during-xtalks-podcast/) 

[Newsramp.com TLDR](https://newsramp.com/None) 